STOCK TITAN

InspireMD CEO buys 46,154 shares in offering

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

InspireMD, Inc. (NSPR) CEO and President Marvin Slosman reported buying 46,154 common shares and 34,616 Series L common stock warrants in the issuer’s underwritten public offering on November 13, 2026. The combined public offering price was $0.65 per share of common stock and accompanying warrants. After the transactions, he directly held 3,602,812 common shares and 34,616 warrants. The form reports no Rule 10b5-1 plan for these transactions.

Insider Slosman Marvin
Role CEO and President
Bought 80,770 shs ($30K)
Type Security Shares Price Value
Purchase Series L Common Stock Warrant F2 34,616 $0.00 $0.00
Purchase Common Stock F1 46,154 $0.65 $30K
Holdings After Transaction: Series L Common Stock Warrant — 34,616 warrants (Direct); Common Stock — 3,602,812 shares (Direct)
Footnotes (2)
  1. F1. Represents shares of common stock purchased by the Reporting Person in the Issuer's underwritten public offering at a combined public offering price of $0.65 per share of common stock and accompanying Series L common stock warrants.
  2. F2. The Series L common stock warrants are immediately exercisable at an exercise price of $0.65 per share and expire on November 16, 2027.
Common shares purchased 46,154 shares November 13, 2026
Combined public offering price $0.65 per share Per share of common stock and accompanying Series L warrants
Series L warrants acquired 34,616 warrants November 13, 2026
Common shares held after transaction 3,602,812 shares Direct holdings following the reported purchase
Warrant exercise price $0.65 per share Series L common stock warrants
Warrant expiration date November 16, 2027 Series L common stock warrants
underwritten public offering financial
"in the Issuer’s underwritten public offering"
An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.
Series L common stock warrants technical
"The Series L common stock warrants are immediately exercisable"
immediately exercisable technical
"are immediately exercisable at an exercise price of $0.65 per share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many NSPR shares did Marvin Slosman buy?

InspireMD CEO and President Marvin Slosman purchased 46,154 common shares on November 13, 2026, in the company’s underwritten public offering at a combined public offering price of $0.65 per share of common stock and accompanying Series L warrants. Afterward, he directly held 3,602,812 common shares. The form reports no Rule 10b5-1 plan for these transactions.

What are the terms of the NSPR Series L warrants Slosman purchased?

Slosman acquired 34,616 Series L common stock warrants. They are immediately exercisable at $0.65 per share and expire November 16, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Slosman Marvin

(Last)(First)(Middle)
C/O INSPIREMD, INC.
6303 WATERFORD DISTRICT DRIVE, SUITE 215

(Street)
MIAMI FLORIDA 33126

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
InspireMD, Inc. [ NSPR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
CEO and President
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/13/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/13/2026P46,154(1)A$0.653,602,812D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Series L Common Stock Warrant(2)$0.6511/13/2026P34,61611/16/202611/16/2027Common Stock34,616$0.0034,616D
Explanation of Responses:
1. Represents shares of common stock purchased by the Reporting Person in the Issuer's underwritten public offering at a combined public offering price of $0.65 per share of common stock and accompanying Series L common stock warrants.
2. The Series L common stock warrants are immediately exercisable at an exercise price of $0.65 per share and expire on November 16, 2027.
/s/ Michael Lawless, Attorney-in-Fact for Marvin Slosman11/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading